SEC Form 4 · accession 0001250853-15-000077
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J Knapp
Officer — General Counsel
Period of report
Jun 25, 2015
Accepted (ET)
Jul 16, 2015 · 9:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.83 | Jun 25, 2015 | A | 40,000 | A | — | Jun 25, 2025 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.
- F2The stock option vests in six approximately equal monthly installments as of the end of each month commencing July 31, 2015 and ending December 31, 2015, subject to the Reporting Person remaining in the Issuer's continuous employ through each monthly vesting date.